Anteris Technologies (ASX:AVR) (OTCMKTS:AMEUF) (FRA:DDF) achieved another standout year in 2020 as the company made great progress in fulfilling its vision of being a market leader in combating aortic stenosis, with 2021 also looking very promising.
In its 2020 annual report, chairman John Seaberg said not only did Anteris begin the first-in-human trial of its 3D-single piece DurAVR™ aortic valve, but the business also celebrated a new company name to signify its focus on developing innovative products and solutions in the structural heart space.
“On the right strategic path”
He continued: “The progress of the first-in-human surgical trial of the DurAVR™ aortic valve during 2020 was truly significant for Anteris.
“The trial in Belgium, which is continuing in 2021 under globally respected cardiac surgeon, Professor Bart Meuris MD PhD of University Hospitals, Leuven in Belgium, has already produced outstanding preliminary results.
“These results were recognised at the prestigious PCR London Valves 2020 virtual conference, where the DurAVR™ valve was named “Best Innovation” after a competitive, peer-reviewed selection process.
“Such recognition reinforces that we are on the right strategic path and are well-placed to create value for shareholders.”
“2021 already looking very promising”
Seaberg added that 2021 is already looking very promising with the company having secured a $20 million funding package from a New York-based investment fund, Mercer Street Global Opportunity Fund in January to assist with TAVR research and development.
“Later in 2021, we expect to commence an FDA-approved first-in-human clinical study of our TAVR delivery system in the US, which will be another milestone achievement for the company.
“Thank you for your continued support over 2020, a year that was built upon the transformational year of 2019, when we favourably divested non-core businesses.”
“Created value for investors"
Managing director and CEO Wayne Paterson further reiterated the company’s year of milestones in 2020 by adding that the name change in May signified its transformation to a full-scale-development structural heart company focused on delivering clinically superior solutions that improve the lives of patients.
He said: “Anteris experienced only minor impacts from the COVID-19 pandemic impact during 2020, after taking early steps to mitigate risk.
“The impact of COVID-19 slowed the first-inhuman trial in Belgium, but Anteris’ contract manufacturing for LeMaitre Vascular Inc. remained strong.
“The FY20 financial performance reflected the company’s continuing focus on executing strategic initiatives to drive the business on a more sustainable path.
“The significant progress of Anteris’ outstanding “next-generation” technology during 2020 has created value for investors and is set to add more during 2021 and beyond.”